17 January 2019 injectable products, intellectual property and commercial infrastructure from Spectrum Pharma for a cash consideration of USD160m. The acquired products are already commercialized in the US (contributed USD116.2m in CY17 and likely to have contributed ~USD105m in CY18 for Spectrum Pharma). For ARBP, these products are expected to generate sales of ~USD100m for the first 12 months post completion of the deal. portfolio analysis indicates four products are under patent, which are expiring over FY20-34. This is largely due to increased R&D; (76% of sales) and selling expenses (84% of sales) for Spectrum. Post-acquisition of the commercial portfolio by ARBP, the R&D; spend would get eliminated. In addition, selling expenses would reduce considerably as ARBP will use its own marketing platform. Pro forma P&L; (Exhibit 1) indicates PAT of USD10m in FY20, which will only increase on the back of an improvement in sales and profitability.